Literature DB >> 3101558

von Willebrand factor abnormalities in primary pulmonary hypertension.

R L Geggel, A C Carvalho, L W Hoyer, L M Reid.   

Abstract

In primary pulmonary hypertension of recent clinical onset, pulmonary endothelial cells show injury. To characterize this phenomenon, we measured plasma von Willebrand factor (vWF) by immunologic and ristocetin cofactor assays in 6 patients with primary pulmonary hypertension, 17 patients with secondary pulmonary artery hypertension associated with congenital heart disease or cystic fibrosis, and 13 patients with congenital heart disease and normal pulmonary artery pressure. In selected cases, we also determined the vWF multimer pattern. In all 6 cases of primary pulmonary hypertension, the ristocetin cofactor activity was increased relative to the vWF antigen (vWF:Ag) concentration (a ratio of 2.55 +/- 0.36; normal range, 0.8 to 1.4); 4 of the 6 also had a similar and abnormal vWF multimer pattern--an increased proportion of the fastest moving bands. In the other 2, the multimer pattern was normal. Of the other 30 patients, a mild increase in ristocetin cofactor/vWF:Ag was seen in only 2 with secondary pulmonary hypertension and 1 with normal pulmonary artery pressure: these also had an abnormal vWF multimer pattern that was different from that observed in patients with primary pulmonary hypertension. The vWF abnormalities we describe in primary pulmonary hypertension offer a marker of the disease and could be helpful in understanding its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101558     DOI: 10.1164/arrd.1987.135.2.294

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Characterization of von Willebrand factor in primary pulmonary hypertension.

Authors:  M T Collados; J Sandoval; S López; F A Massó; A Páez; J R Borbolla; L F Montaño
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome.

Authors:  D B Rubin; J P Wiener-Kronish; J F Murray; D R Green; J Turner; J M Luce; A B Montgomery; J D Marks; M A Matthay
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

3.  A case of acquired von Willebrand disease in severe pediatric pulmonary hypertension contributing to bleeding following reverse Potts shunt.

Authors:  Rachel T Sullivan; Clara Lo; Elisabeth Martin; Rebecca J Kameny; Rachel K Hopper
Journal:  Pulm Circ       Date:  2022-02-04       Impact factor: 2.886

4.  Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

Authors:  Revathi Rajkumar; Kazuhisa Konishi; Thomas J Richards; David C Ishizawar; Andrew C Wiechert; Naftali Kaminski; Ferhaan Ahmad
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

Review 5.  von Willebrand factor and its relevance to cardiovascular disorders.

Authors:  G Y Lip; A D Blann
Journal:  Br Heart J       Date:  1995-12

6.  Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension.

Authors:  Barbara O Meyrick; David B Friedman; D Dean Billheimer; Joy D Cogan; Melissa A Prince; John A Phillips; James E Loyd
Journal:  Am J Respir Crit Care Med       Date:  2007-10-11       Impact factor: 21.405

7.  Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis.

Authors:  Theresa Barnes; Angela Gliddon; Caroline J Doré; Peter Maddison; Robert J Moots
Journal:  Rheumatology (Oxford)       Date:  2012-05-16       Impact factor: 7.580

8.  Platelets in pulmonary hypertension: a causative role or a simple association?

Authors:  Keyhan Sayadpour Zanjani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.